DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence

Oncologist

Volumn 16, Issue 10, 2011, Pages 1440-1450

  Menghi, Francesca ^a   Orzan, Francesca N ^a   Eoli, Marica ^a   Farinotti, Mariangela ^a   Maderna, Emanuela ^a   Pisati, Federica ^a   Bianchessi, Donatella ^a   Valletta, Lorella ^a   Lodrini, Sandro ^a   Galli, Giuseppe ^b   Anghileri, Elena ^a   Pellegatta, Serena ^a   Pollo, Bianca ^a   Gaetano, Finocchiaro ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b CREMONA HOSPITAL   (Italy)

Author keywords

Cyclin kinase; DNA microarray; Leptin receptor; Loss of heterozygosity; Meningiomas

Indexed keywords

BACULOVIRUS INHIBITOR OF APOPTOSIS REPEAT CONTAINING 5 PROTEIN; CYCLIN DEPENDENT KINASE REGULATORY SUBUNIT 2; GENE PRODUCT; LEPTIN RECEPTOR; LIM DOMAIN AND ACTIN BINDING 1 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ARTICLE; BACULOVIRUS INHIBITOR OF APOPTOSIS REPEAT CONTAINING 5 GENE; CANCER GRADING; CANCER GROWTH; CANCER RELAPSE; CELL NUCLEUS; CHROMOSOME 10Q; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 9P; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE REGULATORY SUBUNIT 2 GENE; CYTOPLASM; DNA MICROARRAY; DOWN REGULATION; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEPTIN RECEPTOR GENE; LIM DOMAIN AND ACTIN BINDING 1 GENE; MENINGIOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; TISSUE INHIBITOR OF METALLOPROTEINASE 3 GENE; TUMOR RECURRENCE; UPREGULATION;

CARRIER PROTEINS; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICROARRAY ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LEPTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 80054828096     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0249     Document Type: Article

References (47)

1. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 2011;30:2333-2344.
2. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004;63:275-286.
3. Vernooij MW, Ikram MA, Tanghe HL et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357:1821-1828.
4. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008;26: 279-282.
5. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
6. Weber DC, Lovblad KO, Rogers L. New pathology classification, imagery techniques and prospective trials for meningiomas: The future looks bright. Curr Opin Neurol 2010;23:563-570.
7. Perry A, Scheithauer BW, Stafford SL et al. "Malignancy" in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85:2046-2056.
8. Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 2009;92:1-6.
9. Wen PY, Yung WK, Lamborn KR et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009;11:853-860.
10. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009;9:231-240.
11. Ruttledge MH, Sarrazin J, Rangaratnam S et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-184.
12. Lekanne Deprez RH, Bianchi AB, Groen NA et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994;54:1022-1029.
13. Kim JH, Kim IS, Kwon SY et al. Mutational analysis of the NF2 gene in sporadic meningiomas by denaturing high-performance liquid chromatography. Int J Mol Med 2006;18:27-32.
14. Curto M, McClatchey AI. Nf2/Merlin: A coordinator of receptor signaling and intercellular contact. Br J Cancer 2008;98:256-262.
15. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006;5:1045-1054.
16. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010;99:379-391.
17. Boström J, Meyer-Puttlitz B, Wolter M et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas Am J Pathol 2001;159:661-669.
18. GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
20. Tseng KY, Chung MH, Sytwu HK et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol 2010;100:217-223.
21. Cai DX, Banerjee R, Scheithauer BW et al. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001;60:628-636.
22. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R et al. Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 2004;148:123-128.
23. Leuraud P, Dezamis E, Aguirre-Cruz L et al. Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 2004;100:303-309.
24. Martinez-Glez V, Alvarez L, Franco-Hernàndez C et al. Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. Cancer Genet Cytogenet 2010;196:1-6.
25. Weber RG, Boström J, Wolter M et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-14724.
26. Leone PE, Bello MJ, de Campos JM et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18: 2231-2239.
27. Buccoliero AM, Castiglione F, Degl'Innocenti DR et al. NF2 gene expression in sporadic meningiomas: Relation to grades or histotypes real time- PCR study. Neuropathology 2007;27:36-42.
28. Schiffer D, Ghimenti C, Fiano V. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol 2005;73:125-130.
29. Al-Mefty O, Kadri PA, Pravdenkova S et al. Malignant progression in meningioma: Documentation of a series and analysis of cytogenetic findings. J Neurosurg 2004;101:210-218.
30. Wrobel G, Roerig P, Kokocinski F et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005;114: 249-256.
31. Carvalho LH, Smirnov I, Baia GS et al. Molecular signatures define two main classes of meningiomas. Mol Cancer 2007;6:64.
32. Fèvre-Montange M, Champier J, Durand A et al. Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype. Int J Oncol 2009;35:1395-1407.
33. Li M, Lin YM, Hasegawa S et al. Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol 2004;24:305-312.
34. Wiese AH, Auer J, Lassmann S et al. Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 2007;31:282-295.
35. Lan Y, Zhang Y, Wang J et al. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer 2008;123:543-551.
36. Kang MA, Kim JT, Kim JH et al. Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. J Cancer Res Clin Oncol 2009;135:761-769.
37. Shen DY, Fang ZX, You P et al. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int 2010; 30:119-125.
38. Rother K, Dengl M, Lorenz J et al. Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73. FEBS Lett 2007;581:1166-1172.
39. Verheijen FM, Sprong M, Kloosterman JM et al. TP53 mutations in human meningiomas. Int J Biol Markers 2002;17:42-48.
40. Aguiar PH, Agner C, Simm R et al. p53 protein expression in meningiomas- a clinicopathologic study of 55 patients. Neurosurg Rev 2002;25: 252-257.
41. Yang SY, Park CK, Park SH et al. Atypical and anaplastic meningiomas: Prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008;79:574-580.
42. Kamei Y, Watanabe M, Nakayama T et al. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neurooncol 2000;46:205-213.
43. Picó C, Sànchez J, Oliver P et al. Leptin production by the stomach is up-regulated in obese (fa/fa) Zucker rats. Obes Res 2002;10:932-938.
44. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004;13:215-223.
45. Jacobs DH, McFarlane MJ, Holmes FF. Meningiomas and obesity reconsidered. Ann Neurol 1986;20:376.
46. Schneider B, Pülhorn H, Röhrig B et al. Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prev 2005;29:440-447.
47. Aghi MK, Eskandar EN, Carter BS et al. Increased prevalence of obesity and obesity-related postoperative complications in male patients with meningiomas. Neurosurgery 2007;61:754-760; discussion 760-761.